论文部分内容阅读
目的:检测人滋养层细胞表面抗原-2(TROP-2)在人肺腺癌组织和细胞系中的表达,探讨其与临床病理因素和预后的关系。方法:流式细胞术检测5株人肺腺癌细胞系、1株永生化正常人支气管上皮细胞系中TROP-2的表达,RT-PCR检测11例、免疫组化检测46例肺腺癌组织中TROP-2的表达,并结合临床病理因素及预后进行分析。结果:人肺腺癌细胞系中H1975、SPCA-1和PC-9有TROP-2表达,表达阳性率分别为(45.3±5.4)%、(91.4±4.6)%和(97.2±2.1)%,而在A549、H1299及正常人支气管上皮细胞系HBE中无表达。TROP-2 mRNA的表达阳性率为72.7%(8/11)。TROP-2蛋白在肺腺癌组织中的阳性率(43.5%,20/46)明显高于癌旁正常肺组织(0,0/11)和肺良性病变组织(9.5%,2/21),P=0.001。肺腺癌TROP-2的表达与肿瘤淋巴结转移(P=0.02)和TNM分期(P=0.02)相关,与患者术后生存期呈负相关趋势,但差异无统计学意义,P=0.068。结论:TROP-2在肺腺癌组织及肺腺癌细胞系中均有较高表达,可能在肺腺癌发生发展中发挥重要作用。
OBJECTIVE: To detect the expression of human trophoblast cell surface antigen-2 (TROP-2) in human lung adenocarcinoma tissues and cell lines and to explore its relationship with clinicopathological parameters and prognosis. Methods: Flow cytometry was used to detect the expression of TROP-2 in 5 human lung adenocarcinoma cell lines and 1 immortalized normal human bronchial epithelial cell line. RT-PCR was used to detect the expression of TROP-2 in 11 human lung adenocarcinoma cell lines and 46 lung adenocarcinoma tissues TROP-2 expression, combined with clinical and pathological factors and prognosis analysis. Results: The expression of TROP-2 in H1975, SPCA-1 and PC-9 cells was (45.3 ± 5.4)%, (91.4 ± 4.6)% and (97.2 ± 2.1)% respectively in human lung adenocarcinoma cell lines, But not in A549, H1299 and normal human bronchial epithelial cell line HBE. The positive rate of TROP-2 mRNA expression was 72.7% (8/11). The positive rate of TROP-2 protein in lung adenocarcinoma (43.5%, 20/46) was significantly higher than that in adjacent normal lung tissues (0,0 / 11) and benign lung tissues (9.5%, 2/21) P = 0.001. The expression of TROP-2 in lung adenocarcinoma was correlated with tumor lymph node metastasis (P = 0.02) and TNM stage (P = 0.02), but negatively correlated with postoperative survival, but the difference was not statistically significant (P = 0.068). CONCLUSION: TROP-2 is highly expressed in both lung adenocarcinoma and lung adenocarcinoma cell lines and may play an important role in the development of lung adenocarcinoma.